Sulfasalazine-Induced Pancytopenia in Ulcerative Colitis

Authors

  • NS Neki Professor, Department of Medicine, Government Medical College/Guru Nanak Dev Hospital, Amritsar
  • Ankur Jain Junior Resident, Department of Medicine, Government Medical College/Guru Nanak Dev Hospital, Amritsar

DOI:

https://doi.org/10.3329/jemc.v6i3.29685

Keywords:

Sulfasalazine, Ulcerative colitis, Pancytopenia, Myelosuppression

Abstract

Sulfasalazine is a well-established disease-modifying agent. It is commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. The most frequently reported adverse effects are gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. Patients treated with sulfasalazine can develop thrombocytopenia which is immune mediated. We report a case of ulcerative colitis that was on sulfasalazine subsequently developing thrombocytopenia.

J Enam Med Col 2016; 6(3): 164-165

Downloads

Download data is not yet available.
Abstract
53
PDF
121

Author Biography

NS Neki, Professor, Department of Medicine, Government Medical College/Guru Nanak Dev Hospital, Amritsar



Downloads

Published

2016-10-20

How to Cite

Neki, N., & Jain, A. (2016). Sulfasalazine-Induced Pancytopenia in Ulcerative Colitis. Journal of Enam Medical College, 6(3), 164–165. https://doi.org/10.3329/jemc.v6i3.29685

Issue

Section

Case Reports